

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (withdrawn) A method for enhancing preservative efficacy of an ophthalmic composition, the composition comprising  
0.001 wt% to 0.05 wt% of zinc,  
an organic, nitrogen-containing preservative agent,  
a borate buffer, and  
0 wt% to 0.01 wt% of a chelating agent, wherein the composition has an osmolality of from 225 mOsm.kg to 400 mOsm/kg.

Claims 2. – 5. Canceled

6. (withdrawn) The method of claim 1, further comprising a cationic cellulosic polymer.

7. (withdrawn) The method of claim 6, wherein the composition has a minimum of 0.001 wt.% and a maximum of 0.5 wt.% cationic cellulosic polymer.

8. (withdrawn) The method of claim 7, wherein the cationic cellulosic polymer is Polymer JR.

Claims 9. – 12. Canceled

13. (withdrawn) The method of claim 1, wherein the composition further comprises a therapeutically effective amount of therapeutic agent selected from the group comprising glaucoma agents, muscarinics, carbonic anhydrase inhibitors, dopaminergic agonists and antagonists, anti-infectives, non-steroidal and steroidal anti-inflammatories, prostaglandins, enzymes, growth factors, anti-allergics, beta-blockers and mixtures and combinations thereof.

Claims 14. – 24. Canceled

25. (withdrawn) The method of claim 1, wherein the composition has the form of an eye drop solution.

26. (withdrawn) The method of claim 1, wherein the composition has the form of a contact lens treating solution.

27. (withdrawn) The method of claim 1, wherein the composition is suitable for direct instillation in the eye without causing irritation to eye tissue.

Claims 28. Canceled

29. (previously amended) An ophthalmic composition comprising:  
water;  
0.001 wt% to 0.05 wt% of zinc,  
an organic, nitrogen-containing preservative agent,  
a borate buffer, and  
0 wt% to 0.01 wt% of a chelating agent, wherein the composition has an osmolality of from 225 mOsm/kg to 400 mOsm/kg.

Claims 30. – 34. Canceled

35. (previously amended) The composition of claim 29, further comprising a cationic cellulosic polymer.

36. (previously amended) The composition of claim 35, wherein the composition has a minimum of 0.001 wt.% and a maximum of 0.5 wt.% of cationic cellulosic polymer.

37. (previously amended) The composition of claim 36, wherein the cationic cellulosic polymer is Polymer JR.

Claims 38. – 39. Canceled

40. (original) The composition of claim 29, having the form of an eye drop solution.

41. (original) The composition of claim 29, having the form of a contact lens treating solution.

42. (original) The composition of claim 29, being suitable for direct instillation in the eye without irritation to eye tissue.

43. (previously amended) The composition of claim 29, further comprising a therapeutic agent is selected from the group consisting of glaucoma agents, muscarinics, carbonic anhydrase inhibitors, dopaminergic agonists and antagonists, anti-infectives, non-steroidal and steroidal anti-inflammatories, prostaglandins, enzymes, growth factors, anti-allergics, beta-blockers and mixtures and combinations thereof.

44. (previously amended) A method of treating an ophthalmic condition comprising administering a composition of claim 43.

Claims 45. – 78. Canceled